Products
Platform
Research
Market
Learn
Compare Nippon India Pharma Fund vs SBI Healthcare Opportunities Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | 3.0 | 5.0 |
Min SIP Amount | ₹100 | ₹500 |
Expense Ratio | 1.8 | 1.93 |
NAV | ₹515.92 | ₹438.21 |
Fund Started | 10 May 2004 | 04 Jun 1999 |
Fund Size | ₹8113.59 Cr | ₹3933.26 Cr |
Exit Load | Exit load of 1% if redeemed within 1 month. | Exit load of 0.50% if redeemed within 15 days |
Risk
Very High
Very High
Rating
3.0
5.0
Min SIP Amount
₹100
₹500
Expense Ratio
1.8
1.93
NAV
₹515.92
₹438.21
Fund Started
10 May 2004
04 Jun 1999
Fund Size
₹8113.59 Cr
₹3933.26 Cr
Exit Load
Exit load of 1% if redeemed within 1 month.
Exit load of 0.50% if redeemed within 15 days
Returns
1 Year | 1.70% | 5.54% |
3 Year | 21.60% | 25.35% |
5 Year | 18.48% | 20.25% |
1 Year
1.70%
5.54%
3 Year
21.60%
25.35%
5 Year
18.48%
20.25%
Holding Analysis
Equity | 99.44% | 96.36% |
Cash | 0.56% | 3.56% |
Equity
99.44%
96.36%
Cash
0.56%
3.56%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 12.29% |
Lupin Ltd. | 7.26% |
Divi's Laboratories Ltd. | 7.01% |
Cipla Ltd. | 6.48% |
Apollo Hospitals Enterprise Ltd. | 5.92% |
Dr. Reddy's Laboratories Ltd. | 5.91% |
Vijaya Diagnostic Centre Ltd. | 3.56% |
Medplus Health Services Ltd. | 3.39% |
Gland Pharma Ltd. | 3.24% |
Glaxosmithkline Pharmaceuticals Ltd. | 2.99% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 10.94% |
Divi's Laboratories Ltd. | 6.36% |
Max Healthcare Institute Ltd. | 5.67% |
Cipla Ltd. | 4.59% |
Lupin Ltd. | 4.08% |
Lonza Group Ag | 4.06% |
Fortis Healthcare Ltd. | 3.70% |
Torrent Pharmaceuticals Ltd. | 3.66% |
Gland Pharma Ltd. | 3.54% |
Mankind Pharma Ltd. | 3.34% |
Fund Manager
Name | Akshay Sharma | Tanmaya Desai |
Start Date | 01 Dec 2022 | 17 May 2024 |
Name
Akshay Sharma
Tanmaya Desai
Start Date
01 Dec 2022
17 May 2024
About Fund
Description | The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies. | The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space. |
Launch Date | 10 May 2004 | 04 Jun 1999 |
Description
The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies.
The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space.
Launch Date
10 May 2004
04 Jun 1999